江苏蓝丰生物化工股份有限公司 第七届董事会第二十五次会议决议公告 证券代码：002513 证券简称：蓝丰生化 公告编号：2025-039 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏蓝丰生物化工股份有限公司（以下简称"公司"）第七届董事会第二十 五次会议于 2025 年 8 月 27 日以通讯表决方式召开。本次会议已于 2025 年 8 月 17 日以微信、电子邮件的方式通知全体董事。本次会议由公司董事长郑旭先生 主持，应出席董事 8 人，实际出席董事 8 人，高管列席会议。本次会议的召集、 召开及表决程序符合《公司法》和《公司章程》的规定，合法有效。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 经审核，董事会认为公司《2025 年半年度报告》及《2025 年半年度报告摘 要》的编制程序符合法律、行政法规的规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 该议案经审计委员会审议通过。 表决结果：8 票同意，0 票反对，0 票弃权。 具 ...

江苏蓝丰生物化工股份有限公司 2025 年半年度报告全文 江苏蓝丰生物化工股份有限公司 2025 年半年度报告 2025 年 8 月 本报告涉及对未来发展的展望等前瞻性陈述，不构成公司对投资者的实质 承诺，存在一定的不确定性，投资者及相关人士应当对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异，敬请广大投资者注意投资 风险。 公司在本半年度报告中详细阐述了未来可能发生的有关风险因素及对策， 详见"第三节 管理层讨论与分析"之" 十、公司面临的风险和应对措施"， 敬请投资者予以关注，并注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 1 1 江苏蓝丰生物化工股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人李质磊、主管会计工作负责人邢军及会计机构负责人(会计主 管人员)邢军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 | | 1 | ...

Group 1 - The core point of the article is that Lanfeng Biochemical announced the approval of several proposals at its first extraordinary general meeting of shareholders in 2025, including adjustments to the performance assessment indicators for the 2024 restricted stock incentive plan [2] Group 2 - The company held its first extraordinary general meeting of shareholders in 2025 on August 15 [2] - The meeting reviewed and approved the proposal regarding the adjustment of performance assessment indicators for the 2024 restricted stock incentive plan [2] - Multiple proposals were discussed and approved during the meeting [2]

Meeting Details - The meeting was held on August 15, 2025, at 14:30 [1] - Network voting was available on the same day from 9:15 to 15:00 [1] Attendance - A total of 132 shareholders attended the meeting, representing 107,278,555 shares, which is 28.5862% of the total voting shares [1] - 124 shareholders participated via network voting, representing 6,048,000 shares, which is 1.6116% of the total voting shares [2] Voting Results - The meeting utilized a combination of on-site voting and network voting [2] - For a specific proposal, 73,537,532 shares were in favor, accounting for 99.9457% of the valid votes cast [2] - Among the small shareholders present, 4,760,100 shares voted in favor, representing 78.7054% of their valid votes [2] - The proposal was passed as it received more than two-thirds of the votes from shareholders present [2] Legal Compliance - The qualifications of attendees, the convening of the meeting, voting procedures, and results were confirmed to comply with Chinese laws and regulations [4] - No proposals were changed or rejected during the meeting, and the resolutions passed were deemed legal and valid [4]

Core Viewpoint - The legal opinion letter from Beijing Wan Shang Tian Qin Law Firm confirms that the procedures for the convening and holding of Jiangsu Lanfeng Bio-chemical Co., Ltd.'s 2025 first extraordinary general meeting of shareholders comply with relevant laws and regulations [2][4][6]. Group 1: Meeting Procedures - The extraordinary general meeting was convened by the company's board of directors, with the decision made on July 28, 2025, to hold the meeting on August 15, 2025 [2][3]. - A notice regarding the meeting was published on July 30, 2025, detailing the convenor, meeting time, method, and other relevant matters [3]. - The meeting utilized a combination of on-site voting and online voting, with specific time slots allocated for each method [3]. Group 2: Attendance and Voting - A total of 132 shareholders and their representatives attended the meeting, representing 113,326,555 shares, which is 30.1978% of the total shares [4]. - Of the attendees, 8 were present at the on-site meeting, representing 107,278,555 shares (28.5862%), while 124 participated via online voting, representing 6,048,000 shares (1.6116%) [4]. - The voting results showed that the proposals were overwhelmingly approved, with significant majorities in favor [6][8]. Group 3: Voting Results - The first proposal received 73,537,532 votes in favor, accounting for 98.2788% of the votes cast [5]. - The second proposal was approved with 113,139,155 votes in favor, representing 99.8346% of the total votes [6]. - The third proposal also passed with 113,144,455 votes in favor, which is 99.8393% of the total votes [8]. Group 4: Conclusion - The law firm concluded that all aspects of the meeting, including the convening procedures, qualifications of attendees, and voting processes, were in compliance with legal and regulatory requirements, rendering the resolutions valid [6].

北京市万商天勤律师事务所 关于 江苏蓝丰生物化工股份有限公司 2025 年第一次临时股东会 的法律意见书 北京市朝阳区建国门外大街 8 号北京国际财源中心 A 座 32 层 100022 电话: +86 10 82255588 www.vtlaw.cn 北京 深圳 上海 成都 武汉 西安 长沙 杭州 海口 南京 广州 香港(联营) 昆明 福州 北京市万商天勤律师事务所 关于江苏蓝丰生物化工股份有限公司 2025 年第一次临时股东会的 法律意见书 致：江苏蓝丰生物化工股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》及中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）《深圳证券交易所上市 公司股东会网络投票实施细则》等法律、法规和规范性文件的规定，北京市万商天勤 律师事务所（以下称"本所"）接受江苏蓝丰生物化工股份有限公司（以下简称"公 司"）的委托，指派律师现场出席公司 2025 年第一次临时股东会，并出具法律意见。 本所律师同意将本法律意见书随公司本次股东会决议一并予以公告，并依法对本 法律意见书承担相应的责任。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认 ...

江苏蓝丰生物化工股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 一、特别提示： 1、本次股东会未出现否决议案的情形。 证券代码：002513 证券简称：蓝丰生化 公告编号：2025-037 2、本次股东会不涉及变更前次股东会决议。 二、会议召开情况 1、会议召开方式：本次股东会采用现场投票与网络投票相结合的方式。 2、召开时间 （1）现场会议召开时间为：2025 年 8 月 15 日（星期五）下午 14：30。 （2）网络投票时间为：2025 年 8 月 15 日。其中： ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 8 月 15 日 9：15～9：25、9：30～11：30、13：00～15：00； ②通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 8 月 15 日上午 9：15 至下午 15：00 期间的任意时间。 3、现场会议召开地点：安徽省滁州市中新苏滁高新技术产业开发区建业路 1 号旭合科技办公楼 202 会议室。 4、召集人：江苏蓝丰生物化工股份有限公司董事会 ...

证券之星消息，8月14日农化制品板块较上一交易日下跌1.35%，宏达股份领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。农化制品板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600331 | 宏达股份 | 10.02 | -5.47% | 63.40万 | 6.50亿 | | 870866 | 绿亭科技 | 9.52 | -4.42% | 3.56万 | 3457.43万 | | 002734 | 利民股份 | 21.65 | -4.12% | 38.98万 | 8.67 Z | | 002513 | 蓝丰生化 | 5.46 | -3.87% | 8.22万 | 4571.81万 | | 600596 | 新安股份 | 9.67 | -3.40% | 27.83万 | 2.74亿 | | 30 ...

Market Overview - The Shanghai Composite Index is at 3568.96 points with a change of 0.25% [1] - The total trading volume of A-shares is 11803.88 billion yuan [1] Technical Analysis - 42 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sifang Precision (300468) with a distance of -1.65% [1] - Zhongyou Capital (000617) with a distance of -1.06% [1] - Langxin Group (300682) with a distance of -0.89% [1] Individual Stock Performance - Sifang Precision (300468) has decreased by 1.63% today with a turnover rate of 5.43% [1] - Zhongyou Capital (000617) has decreased by 3.65% today with a turnover rate of 1.65% [1] - Langxin Group (300682) has decreased by 0.86% today with a turnover rate of 1.91% [1] - Other stocks with notable performance include: - China Life Insurance (601319) with a slight increase of 0.12% [1] - Haosen Intelligent (688529) with an increase of 1.31% [1] - Donglai Technology (688129) with an increase of 1.88% [1] Additional Stock Data - Stocks showing a decrease in their 5-day moving average compared to the 10-day moving average include: - Mengjie (002397) down by 1.39% [1] - Greenland Holdings (600606) down by 0.53% [1] - Lida Xin (605365) down by 0.88% [1] - Stocks with minor changes include: - Jiemai (300868) down by 0.23% [2] - Lianchuang Electronics (002036) up by 0.19% [2] - ST Panda (600599) up by 0.26% [2]

Core Viewpoint - Jiangsu Lanfeng Biological Chemical Co., Ltd. is currently involved in a legal dispute regarding securities false statements, with a total claim amount of RMB 19.18 million from 163 investors [2][3][4]. Group 1: Lawsuit Basic Information - The company has previously disclosed information regarding the investor lawsuit related to securities false statements [3]. - The final judgment and civil rulings from the Nanjing Intermediate People's Court have been received concerning the claims from 45 investors [3]. Group 2: Lawsuit Progress - The Nanjing Intermediate People's Court has issued an execution ruling to freeze RMB 19.18 million of the company's bank deposits due to non-compliance with a prior civil judgment [4]. - A total of 8 bank accounts of the company have been frozen, with only RMB 77,400 actually frozen [4]. - The company's overall business operations remain normal and unaffected by the bank account freeze [4]. Group 3: Company Response - The company plans to raise funds to comply with the court ruling and compensate the investors, aiming to lift the freezing measures promptly [5]. - The company will pursue accountability against its former directors and senior management as per the administrative penalty decision issued by the China Securities Regulatory Commission [5]. Group 4: Financial Impact - The total amount related to the investor lawsuit and associated costs is approximately RMB 19.18 million, which will be accounted for as liabilities and losses according to accounting standards [7]. - The company will continue to monitor the lawsuit's progress and fulfill its information disclosure obligations [7].